Short answer
Larimar Therapeutics, Inc. (LRMR) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$30M
- −1.1% YoY
Source: XBRL data from the Larimar Therapeutics, Inc. (LRMR) Q1 2026 10-Q on SEC EDGAR. USD.
Larimar Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk-factors section provided in the submitted text
- No newly added risk identified
- No regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Larimar Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.